Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in rats

Laurence L. Miller, Michael D. Leitl, Matthew L. Banks, Bruce E. Blough, S. Stevens Negus

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Pain-related depression of behavior and mood is a key therapeutic target in the treatment of pain. Clinical evidence suggests a role for decreased dopamine (DA) signaling in pain-related depression of behavior and mood. Similarly, in rats, intraperitoneal injection of dilute lactic acid (IP acid) serves as a chemical noxious stimulus to produce analgesic-reversible decreases in both (1) extracellular DA levels in nucleus accumbens (NAc) and (2) intracranial self-stimulation (ICSS), an operant behavior reliant on NAc DA. Intraperitonial acid-induced depression of ICSS is blocked by DA transporter (DAT) inhibitors, but clinical viability of selective DAT inhibitors as analgesics is limited by abuse potential. Drugs that produce combined inhibition of both DA and serotonin transporters may retain efficacy to block pain-related behavioral depression with reduced abuse liability. Amitifadine is a "triple uptake inhibitor" that inhibits DAT with approximately 5- to 10-fold weaker potency than it inhibits serotonin and norepinephrine transporters. This study compared amitifadine effects on IP acid-induced depression of NAc DA and ICSS and IP acid-stimulated stretching in male Sprague-Dawley rats. Amitifadine blocked IP acid-induced depression of both NAc DA and ICSS and IP acid-stimulated stretching. In the absence of the noxious stimulus, amitifadine increased NAc levels of both DA and serotonin, and behaviorally, amitifadine produced significant but weak abuse-related ICSS facilitation. Moreover, amitifadine was more potent to block IP acid-induced depression of ICSS than to facilitate control ICSS. These results support consideration of amitifadine and related monoamine uptake inhibitors as candidate analgesics for treatment of pain-related behavioral depression.

Original languageEnglish (US)
Pages (from-to)175-184
Number of pages10
JournalPain
Volume156
Issue number1
DOIs
StatePublished - Jan 2015
Externally publishedYes

Fingerprint

Self Stimulation
Dopamine
Nucleus Accumbens
Pain
Acids
Analgesics
Serotonin Plasma Membrane Transport Proteins
Dopamine Plasma Membrane Transport Proteins
Norepinephrine Plasma Membrane Transport Proteins
Depression
1-(3,4-dichlorophenyl)-3-azabicyclo-(3.1.0)hexane hydrochloride
Intraperitoneal Injections
Sprague Dawley Rats
Lactic Acid
Serotonin
Therapeutics
Pharmaceutical Preparations

Keywords

  • Adrenergic Uptake Inhibitors
  • Animals
  • Aza Compounds
  • Bicyclo Compounds, Heterocyclic
  • Depression
  • Dopamine
  • Dopamine Uptake Inhibitors
  • Male
  • Microdialysis
  • Nucleus Accumbens
  • Pain
  • Rats
  • Rats, Sprague-Dawley
  • Serotonin Uptake Inhibitors
  • Treatment Outcome

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in rats. / Miller, Laurence L.; Leitl, Michael D.; Banks, Matthew L.; Blough, Bruce E.; Negus, S. Stevens.

In: Pain, Vol. 156, No. 1, 01.2015, p. 175-184.

Research output: Contribution to journalArticle

Miller, Laurence L. ; Leitl, Michael D. ; Banks, Matthew L. ; Blough, Bruce E. ; Negus, S. Stevens. / Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in rats. In: Pain. 2015 ; Vol. 156, No. 1. pp. 175-184.
@article{eee07974581948e1b01a8479561b1006,
title = "Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in rats",
abstract = "Pain-related depression of behavior and mood is a key therapeutic target in the treatment of pain. Clinical evidence suggests a role for decreased dopamine (DA) signaling in pain-related depression of behavior and mood. Similarly, in rats, intraperitoneal injection of dilute lactic acid (IP acid) serves as a chemical noxious stimulus to produce analgesic-reversible decreases in both (1) extracellular DA levels in nucleus accumbens (NAc) and (2) intracranial self-stimulation (ICSS), an operant behavior reliant on NAc DA. Intraperitonial acid-induced depression of ICSS is blocked by DA transporter (DAT) inhibitors, but clinical viability of selective DAT inhibitors as analgesics is limited by abuse potential. Drugs that produce combined inhibition of both DA and serotonin transporters may retain efficacy to block pain-related behavioral depression with reduced abuse liability. Amitifadine is a {"}triple uptake inhibitor{"} that inhibits DAT with approximately 5- to 10-fold weaker potency than it inhibits serotonin and norepinephrine transporters. This study compared amitifadine effects on IP acid-induced depression of NAc DA and ICSS and IP acid-stimulated stretching in male Sprague-Dawley rats. Amitifadine blocked IP acid-induced depression of both NAc DA and ICSS and IP acid-stimulated stretching. In the absence of the noxious stimulus, amitifadine increased NAc levels of both DA and serotonin, and behaviorally, amitifadine produced significant but weak abuse-related ICSS facilitation. Moreover, amitifadine was more potent to block IP acid-induced depression of ICSS than to facilitate control ICSS. These results support consideration of amitifadine and related monoamine uptake inhibitors as candidate analgesics for treatment of pain-related behavioral depression.",
keywords = "Adrenergic Uptake Inhibitors, Animals, Aza Compounds, Bicyclo Compounds, Heterocyclic, Depression, Dopamine, Dopamine Uptake Inhibitors, Male, Microdialysis, Nucleus Accumbens, Pain, Rats, Rats, Sprague-Dawley, Serotonin Uptake Inhibitors, Treatment Outcome",
author = "Miller, {Laurence L.} and Leitl, {Michael D.} and Banks, {Matthew L.} and Blough, {Bruce E.} and Negus, {S. Stevens}",
year = "2015",
month = "1",
doi = "10.1016/j.pain.0000000000000018",
language = "English (US)",
volume = "156",
pages = "175--184",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in rats

AU - Miller, Laurence L.

AU - Leitl, Michael D.

AU - Banks, Matthew L.

AU - Blough, Bruce E.

AU - Negus, S. Stevens

PY - 2015/1

Y1 - 2015/1

N2 - Pain-related depression of behavior and mood is a key therapeutic target in the treatment of pain. Clinical evidence suggests a role for decreased dopamine (DA) signaling in pain-related depression of behavior and mood. Similarly, in rats, intraperitoneal injection of dilute lactic acid (IP acid) serves as a chemical noxious stimulus to produce analgesic-reversible decreases in both (1) extracellular DA levels in nucleus accumbens (NAc) and (2) intracranial self-stimulation (ICSS), an operant behavior reliant on NAc DA. Intraperitonial acid-induced depression of ICSS is blocked by DA transporter (DAT) inhibitors, but clinical viability of selective DAT inhibitors as analgesics is limited by abuse potential. Drugs that produce combined inhibition of both DA and serotonin transporters may retain efficacy to block pain-related behavioral depression with reduced abuse liability. Amitifadine is a "triple uptake inhibitor" that inhibits DAT with approximately 5- to 10-fold weaker potency than it inhibits serotonin and norepinephrine transporters. This study compared amitifadine effects on IP acid-induced depression of NAc DA and ICSS and IP acid-stimulated stretching in male Sprague-Dawley rats. Amitifadine blocked IP acid-induced depression of both NAc DA and ICSS and IP acid-stimulated stretching. In the absence of the noxious stimulus, amitifadine increased NAc levels of both DA and serotonin, and behaviorally, amitifadine produced significant but weak abuse-related ICSS facilitation. Moreover, amitifadine was more potent to block IP acid-induced depression of ICSS than to facilitate control ICSS. These results support consideration of amitifadine and related monoamine uptake inhibitors as candidate analgesics for treatment of pain-related behavioral depression.

AB - Pain-related depression of behavior and mood is a key therapeutic target in the treatment of pain. Clinical evidence suggests a role for decreased dopamine (DA) signaling in pain-related depression of behavior and mood. Similarly, in rats, intraperitoneal injection of dilute lactic acid (IP acid) serves as a chemical noxious stimulus to produce analgesic-reversible decreases in both (1) extracellular DA levels in nucleus accumbens (NAc) and (2) intracranial self-stimulation (ICSS), an operant behavior reliant on NAc DA. Intraperitonial acid-induced depression of ICSS is blocked by DA transporter (DAT) inhibitors, but clinical viability of selective DAT inhibitors as analgesics is limited by abuse potential. Drugs that produce combined inhibition of both DA and serotonin transporters may retain efficacy to block pain-related behavioral depression with reduced abuse liability. Amitifadine is a "triple uptake inhibitor" that inhibits DAT with approximately 5- to 10-fold weaker potency than it inhibits serotonin and norepinephrine transporters. This study compared amitifadine effects on IP acid-induced depression of NAc DA and ICSS and IP acid-stimulated stretching in male Sprague-Dawley rats. Amitifadine blocked IP acid-induced depression of both NAc DA and ICSS and IP acid-stimulated stretching. In the absence of the noxious stimulus, amitifadine increased NAc levels of both DA and serotonin, and behaviorally, amitifadine produced significant but weak abuse-related ICSS facilitation. Moreover, amitifadine was more potent to block IP acid-induced depression of ICSS than to facilitate control ICSS. These results support consideration of amitifadine and related monoamine uptake inhibitors as candidate analgesics for treatment of pain-related behavioral depression.

KW - Adrenergic Uptake Inhibitors

KW - Animals

KW - Aza Compounds

KW - Bicyclo Compounds, Heterocyclic

KW - Depression

KW - Dopamine

KW - Dopamine Uptake Inhibitors

KW - Male

KW - Microdialysis

KW - Nucleus Accumbens

KW - Pain

KW - Rats

KW - Rats, Sprague-Dawley

KW - Serotonin Uptake Inhibitors

KW - Treatment Outcome

UR - http://www.scopus.com/inward/record.url?scp=84979859099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979859099&partnerID=8YFLogxK

U2 - 10.1016/j.pain.0000000000000018

DO - 10.1016/j.pain.0000000000000018

M3 - Article

C2 - 25599313

VL - 156

SP - 175

EP - 184

JO - Pain

JF - Pain

SN - 0304-3959

IS - 1

ER -